Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease.

Bateman RJ, Smith J, Donohue MC, Delmar P, Abbas R, Salloway S, Wojtowicz J, Blennow K, Bittner T, Black SE, Klein G, Boada M, Grimmer T, Tamaoka A, Perry RJ, Turner RS, Watson D, Woodward M, Thanasopoulou A, Lane C, Baudler M, Fox NC, Cummings JL, Fontoura P, Doody RS, GRADUATE I and II Investigators and the Gantenerumab Study Group

Open source

DOI: 10.1056/nejmoa2304430
Published: 2023 Nov 16
Container: The New England journal of medicine
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1056/nejmoa2304430,
  title = {Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease.},
  author = {Bateman RJ and Smith J and Donohue MC and Delmar P and Abbas R and Salloway S and Wojtowicz J and Blennow K and Bittner T and Black SE and Klein G and Boada M and Grimmer T and Tamaoka A and Perry RJ and Turner RS and Watson D and Woodward M and Thanasopoulou A and Lane C and Baudler M and Fox NC and Cummings JL and Fontoura P and Doody RS and GRADUATE I and II Investigators and the Gantenerumab Study Group},
  year = {2023},
  journal = {The New England journal of medicine},
  doi = {10.1056/nejmoa2304430},
  url = {https://doi.org/10.1056/nejmoa2304430}
}

RIS

TY  - JOUR
TI  - Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease.
AU  - Bateman RJ
AU  - Smith J
AU  - Donohue MC
AU  - Delmar P
AU  - Abbas R
AU  - Salloway S
AU  - Wojtowicz J
AU  - Blennow K
AU  - Bittner T
AU  - Black SE
AU  - Klein G
AU  - Boada M
AU  - Grimmer T
AU  - Tamaoka A
AU  - Perry RJ
AU  - Turner RS
AU  - Watson D
AU  - Woodward M
AU  - Thanasopoulou A
AU  - Lane C
AU  - Baudler M
AU  - Fox NC
AU  - Cummings JL
AU  - Fontoura P
AU  - Doody RS
AU  - GRADUATE I and II Investigators and the Gantenerumab Study Group
PY  - 2023
JO  - The New England journal of medicine
DO  - 10.1056/nejmoa2304430
UR  - https://doi.org/10.1056/nejmoa2304430
ER  -

APA

RJ, B., J, S., MC, D., P, D., R, A., S, S., J, W., K, B., T, B., SE, B., G, K., M, B., T, G., A, T., RJ, P., RS, T., D, W., M, W., A, T., C, L., M, B., NC, F., JL, C., P, F., RS, D., & Group, G. I. A. I. I. A. T. G. S. (2023). Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease.. The New England journal of medicine. https://doi.org/10.1056/nejmoa2304430

Source records

pubmed · retrieved 2026-09-25T20:38:20.569Z